Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
After years of misdiagnosis, Rod Fussinger was finally diagnosed with Anti-IgLON5 Associated Autoimmune Encephalitis, and ...
Dagens.com on MSN
This sleep habit could be an early dementia warning
Acting out dreams linked to later cognitive decline.
After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...
“Fallujah was—and remains—a symbol of US war crimes during its occupation of Iraq,” Jarrar tells TRNN. “The message sent ...
Death row intensifies the structured brutalities of the penal system and reminds us why the struggle against the death penalty must also include the fact of prison violence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results